To be used in conjunction with Cayman’s Soluble Epoxide Hydrolase polyclonal antibody (Catalog No.10010146) to block protein-antibody complex formation during analysis for soluble epoxide hydrolase. The metabolism of exogenous and endogenous epoxides relies in part upon the activity of soluble epoxide hydrolase (sEH). The relevance of sEH to hypertension and inflammation makes it a potentially useful clinical drug target. Specifically, the conversion of epoxyeicosatrienoic acids (EpETrEs, EETs) by sEH to the corresponding dihydroxy eicosatrienoic acids (DiHETrEs, DHETs) diminishes their vasodilator activity. Inhibitors of sEH may therefore have clinical utility for treating hypertension and systemic inflammation. Caymans polyclonal antibody is useful for monitoring the quantity and distribution of sEH.